186 related articles for article (PubMed ID: 25117153)
21. Management of pulmonary toxicity associated with targeted anticancer therapies.
Teuwen LA; Van den Mooter T; Dirix L
Expert Opin Drug Metab Toxicol; 2015; 11(11):1695-707. PubMed ID: 26293379
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of mucocutaneous toxicity of target therapy in oncology].
Damsin T; Collignon J; Lebas E; Libon F; Dezfoulian B; Nikkels AF
Rev Med Liege; 2019 Jan; 74(1):7-14. PubMed ID: 30680967
[TBL] [Abstract][Full Text] [Related]
23. [New drugs in oncology and skin toxicity].
Mateus C; Robert C
Rev Med Interne; 2009 May; 30(5):401-10. PubMed ID: 19299041
[TBL] [Abstract][Full Text] [Related]
24. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
25. Incidence and risk of xerosis with targeted anticancer therapies.
Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
J Am Acad Dermatol; 2015 Apr; 72(4):656-67. PubMed ID: 25637330
[TBL] [Abstract][Full Text] [Related]
26. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
[TBL] [Abstract][Full Text] [Related]
27. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.
Curry JL; Torres-Cabala CA; Kim KB; Tetzlaff MT; Duvic M; Tsai KY; Hong DS; Prieto VG
Int J Dermatol; 2014 Mar; 53(3):376-84. PubMed ID: 23879247
[TBL] [Abstract][Full Text] [Related]
28. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
Tang N; Ratner D
Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
[TBL] [Abstract][Full Text] [Related]
29. Targeted therapy for brain metastases.
Davies MA
Adv Pharmacol; 2012; 65():109-42. PubMed ID: 22959025
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
31. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
32. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.
Fischer A; Rosen AC; Ensslin CJ; Wu S; Lacouture ME
Dermatol Ther; 2013; 26(2):135-48. PubMed ID: 23551370
[TBL] [Abstract][Full Text] [Related]
33. Dermatologic toxicity of chemotherapeutic agents.
Payne AS; James WD; Weiss RB
Semin Oncol; 2006 Feb; 33(1):86-97. PubMed ID: 16473647
[TBL] [Abstract][Full Text] [Related]
34. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
35. [Skin toxicity].
Sato A; Hamada K; Imataka H
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1767-72. PubMed ID: 22083182
[TBL] [Abstract][Full Text] [Related]
36. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
37. Targeted therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management.
Varvaresou A; Iakovou K; Mellou F; Myrogiannis D; Papageorgiou S
J Cosmet Dermatol; 2020 Apr; 19(4):782-788. PubMed ID: 31769600
[TBL] [Abstract][Full Text] [Related]
38. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
Favre G
Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
[TBL] [Abstract][Full Text] [Related]
40. [Cutaneous side effects of targeted cancer drugs].
Below J; Homey B; Gerber PA
Hautarzt; 2017 Jan; 68(1):12-18. PubMed ID: 27885401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
